[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654480":3},{"organization":4,"outcomesModule":7,"designInfo":135,"detailedDescription":49,"studyPopulation":49,"armGroups":141,"interventions":158,"overallOfficials":179,"centralContacts":182,"locations":190,"responsibleParty":208,"collaborators":49,"id":210,"slug":211,"hasResults":212,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":49,"eligibilityCriteria":216,"healthyVolunteers":217,"sex":218,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":49,"studyType":224,"phases":225,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":193,"whyStopped":49,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":51,"otherOutcomes":49},[9,13,16,18,20,23,26,28,31,33,35,37,40,42,45,47],{"measure":10,"description":11,"timeFrame":12},"Maximum observed concentration (Cmax) of Navlimetostat","Part 1A, Part 1B, Part 3, Part 4","Up to approximately 3 weeks",{"measure":14,"description":15,"timeFrame":12},"Area under the concentration-time curve from time zero to 192 hours (AUC(0-192)) of Navlimetostat","Part 1A",{"measure":17,"description":15,"timeFrame":12},"(AUC(INF)) of Navlimetostat with the coadministration of itraconazole",{"measure":19,"description":15,"timeFrame":12},"AUC(INF) of Navlimetostat without the coadministration of itraconazole",{"measure":21,"description":22,"timeFrame":12},"Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Navlimetostat","Part 1B, Part 3, Part 4",{"measure":24,"description":25,"timeFrame":12},"AUC(INF) of Navlimetostat with the coadministration of Rifampin","Part 1B",{"measure":27,"description":25,"timeFrame":12},"AUC(INF) of Navlimetostat without the coadministration of Rifampin",{"measure":29,"description":30,"timeFrame":12},"Cmax of Midazolam","Part 2",{"measure":32,"description":30,"timeFrame":12},"AUC(0-T) of Midazolam",{"measure":34,"description":30,"timeFrame":12},"AUC(INF) of Midazolam with the coadministration of Navlimetostat",{"measure":36,"description":30,"timeFrame":12},"AUC(INF) of Midazolam without the coadministration of Navlimetostat",{"measure":38,"description":39,"timeFrame":12},"AUC(INF) of Navlimetostat with a high fat meal","Part 3",{"measure":41,"description":39,"timeFrame":12},"AUC(INF) of Navlimetostat without a high fat meal",{"measure":43,"description":44,"timeFrame":12},"AUC(INF) of Navlimetostat with the coadministration of Pantoprazole","Part 4",{"measure":46,"description":44,"timeFrame":12},"AUC(INF) of Navlimetostat without the coadministration of Pantoprazole",{"measure":48,"description":49,"timeFrame":50},"Drug-related AEs",null,"Up to approximately 6 weeks",[52,54,56,58,60,62,64,66,68,70,72,74,76,78,80,82,84,86,88,90,92,94,96,98,100,102,104,106,108,111,113,115,117,119,121,123,125,127,129,131,133],{"measure":53,"description":49,"timeFrame":50},"Adverse events (AEs)",{"measure":55,"description":49,"timeFrame":50},"Serious adverse events (SAEs)",{"measure":57,"description":49,"timeFrame":50},"AEs leading to discontinuation of study or study intervention",{"measure":59,"description":49,"timeFrame":50},"Number of participants with clinically significant changes in physical examination (PE)",{"measure":61,"description":49,"timeFrame":50},"Number of participants with clinically significant changes in vital signs (VS)",{"measure":63,"description":49,"timeFrame":50},"Number of participants with clinically significant changes in 12-lead electrocardiograms (ECGs)",{"measure":65,"description":49,"timeFrame":50},"Number of participants with clinically significant changes in clinical laboratory test results",{"measure":67,"description":15,"timeFrame":12},"AUC(0-T) of Navlimetostat",{"measure":69,"description":11,"timeFrame":12},"Time of maximum observed concentration (Tmax) of Navlimetostat",{"measure":71,"description":11,"timeFrame":12},"Half-life (T-HALF) of Navlimetostat",{"measure":73,"description":11,"timeFrame":12},"Apparent total body clearance (CLT\u002FF) of Navlimetostat",{"measure":75,"description":11,"timeFrame":12},"Apparent volume of distribution at terminal phase (Vz\u002FF) of Navlimetostat",{"measure":77,"description":30,"timeFrame":12},"Tmax of Midazolam",{"measure":79,"description":30,"timeFrame":12},"T-HALF of Midazolam",{"measure":81,"description":30,"timeFrame":12},"CLT\u002FF of Midazolam",{"measure":83,"description":30,"timeFrame":12},"Vz\u002FF of Midazolam",{"measure":85,"description":49,"timeFrame":12},"Cmax of Navlimetostat Metabolite",{"measure":87,"description":49,"timeFrame":12},"AUC(0-T) of Navlimetostat Metabolite",{"measure":89,"description":49,"timeFrame":12},"AUC(INF) of Navlimetostat Metabolite",{"measure":91,"description":15,"timeFrame":12},"AUC(0-192) of Navlimetostat Metabolite",{"measure":93,"description":30,"timeFrame":12},"AUC(0-24) of Navlimetostat Metabolite",{"measure":95,"description":49,"timeFrame":12},"Tmax of Navlimetostat Metabolite",{"measure":97,"description":49,"timeFrame":12},"T-HALF of Navlimetostat Metabolite",{"measure":99,"description":49,"timeFrame":12},"Mean ratio (MR)_Cmax of Navlimetostat Metabolite",{"measure":101,"description":49,"timeFrame":12},"MR_AUC(0-T) of Navlimetostat Metabolite",{"measure":103,"description":49,"timeFrame":12},"MR_AUC(INF) of Navlimetostat Metabolite",{"measure":105,"description":15,"timeFrame":12},"MR_AUC(0-192) of Navlimetostat Metabolite",{"measure":107,"description":30,"timeFrame":12},"MR_AUC(0-24) of Navlimetostat Metabolite",{"measure":109,"description":110,"timeFrame":12},"Cmax of Rifampin","Part 1A and Part 1B",{"measure":112,"description":110,"timeFrame":12},"Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of Rifampin",{"measure":114,"description":110,"timeFrame":12},"Trough observed concentration (Ctrough) of Rifampin",{"measure":116,"description":110,"timeFrame":12},"Tmax of Rifampin",{"measure":118,"description":30,"timeFrame":12},"Cmax of 1-hydroxymidazolam",{"measure":120,"description":30,"timeFrame":12},"AUC(0-T) of 1-hydroxymidazolam",{"measure":122,"description":30,"timeFrame":12},"AUC(INF) of 1-hydroxymidazolam",{"measure":124,"description":30,"timeFrame":12},"Tmax of 1-hydroxymidazolam",{"measure":126,"description":30,"timeFrame":12},"T-HALF of 1-hydroxymidazolam",{"measure":128,"description":30,"timeFrame":12},"MR_Cmax of 1-hydroxymidazolam",{"measure":130,"description":30,"timeFrame":12},"MR_AUC(0-T) of 1-hydroxymidazolam",{"measure":132,"description":30,"timeFrame":12},"MR_AUC(INF) of 1-hydroxymidazolam with the coadministration of Navlimetostat",{"measure":134,"description":30,"timeFrame":12},"MR_AUC(INF) of 1-hydroxymidazolam without the coadministration of Navlimetostat",{"allocation":136,"interventionModel":137,"interventionModelDescription":49,"primaryPurpose":138,"observationalModel":49,"timePerspective":49,"maskingInfo":139},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":140,"maskingDescription":49,"whoMasked":49},"NONE",[142,147,150,153,155],{"label":15,"type":143,"description":49,"interventionNames":144},"EXPERIMENTAL",[145,146],"Drug: Navlimetostat","Drug: Itraconazole",{"label":25,"type":143,"description":49,"interventionNames":148},[145,149],"Drug: Rifampin",{"label":30,"type":143,"description":49,"interventionNames":151},[145,152],"Drug: Midazolam",{"label":39,"type":143,"description":49,"interventionNames":154},[145],{"label":44,"type":143,"description":49,"interventionNames":156},[145,157],"Drug: Pantoprazole",[159,167,170,173,176],{"type":160,"name":161,"description":162,"armGroupLabels":163,"otherNames":164},"DRUG","Navlimetostat","Specified dose on specified days",[15,25,30,39,44],[165,166],"BMS-986504","MRTX-1719",{"type":160,"name":168,"description":162,"armGroupLabels":169,"otherNames":49},"Itraconazole",[15],{"type":160,"name":171,"description":162,"armGroupLabels":172,"otherNames":49},"Rifampin",[25],{"type":160,"name":174,"description":162,"armGroupLabels":175,"otherNames":49},"Midazolam",[30],{"type":160,"name":177,"description":162,"armGroupLabels":178,"otherNames":49},"Pantoprazole",[44],[180],{"name":5,"affiliation":5,"role":181},"STUDY_DIRECTOR",[183,188],{"name":184,"role":185,"phone":186,"phoneExt":49,"email":187},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":189,"role":185,"phone":49,"phoneExt":49,"email":49},"First line of the email MUST contain NCT # and Site #.",[191],{"facility":192,"status":193,"city":194,"state":195,"zip":196,"country":197,"countryCode":198,"cosmosGeoPoint":199,"geoPoint":204,"contacts":205},"Syneos Health Clinique; Inc.","RECRUITING","Québec","Quebec","G1P 0A2","Canada","CA",{"type":200,"coordinates":201},"Point",[202,203],-71.21454,46.81228,{"lat":203,"lon":202},[206],{"name":207,"role":185,"phone":49,"phoneExt":49,"email":49},"Lidia Facchinelli, Site 0001",{"type":209,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100654480","phase-1-a-study-of-navlimetostat-bms-986504-drug-interactions-and-food-effect-in-healthy-participants-100654480",false,"NCT07800897","A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants","A Phase 1, Open-label, Randomized, Pharmacokinetic Study to Assess the Drug Interactions and Food Effect of Navlimetostat (BMS-986504) in Healthy Female Participants","Inclusion Criteria\n\n* Participants must be healthy adult female (as assigned at birth) individuals not of childbearing potential (INOCBP) who have no clinically significant findings on medical history, physical examination (PE), vital signs (VS), 12-lead electrocardiograms (ECGs), or clinical laboratory determinations, as assessed by the investigator.\n* Participants must have a BMI of 18.0 to 35.0 kg\u002Fm2, inclusive.\n\nExclusion Criteria\n\n* Participants must not have any significant acute or chronic medical illness (in the assessment of the investigator).\n* Participants must not have a history of prolonged bleeding or excessive bruising.\n* Participants must not have any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"FEMALE","18 Years","55 Years",{"count":222,"type":223},80,"ESTIMATED","INTERVENTIONAL",[226],"PHASE1","The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants",[229],"Healthy Female Adults",[231,232,233,234,235,236,237,238,239],"PRMT5","MTAP","MRTX1719","MountainTAP","Healthy Adult Female","Individuals not of childbearing potential","Open Label Study","Clinical Research Unit","Phase 1","2026-09-30",{"date":242,"type":243},"2026-10-05","ACTUAL",{"date":245,"type":243},"2026-08-31",{"date":247,"type":223},"2027-03-25",{"name":5,"class":6},1]